Figure 2.
Ruxolitinib pharmacokinetics. Days −2 to +4 (A) and +5 (B). AUC, area under the plasma concentration–time curve; BID, twice daily; CL/F, oral clearance; Cmax, maximum plasma concentration; PK, pharmacokinetics; T1/2, terminal-phase elimination half-life.

Ruxolitinib pharmacokinetics. Days −2 to +4 (A) and +5 (B). AUC, area under the plasma concentration–time curve; BID, twice daily; CL/F, oral clearance; Cmax, maximum plasma concentration; PK, pharmacokinetics; T1/2, terminal-phase elimination half-life.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal